Litigation

Untitled case

listed in Google Patents litigation data

3:11-cv-05579

Patents at issue (1)

7947724

Summary

Listed in Google Patents litigation data for the Helsinn family; whether the '724 patent specifically was asserted was not individually verified.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

I'll research this case and the '724 patent before drafting.

Good — the '724 patent's presence in this docket is confirmed. Let me pin down the docket specifics, defendants, and IPR history.

Now let me check the IPR/PGR record on the '724 patent specifically and the post-Supreme Court aftermath.

Case Overview: Helsinn Healthcare S.A. v. [Dr. Reddy's Laboratories, Ltd.](/litigations/by-plaintiff/Dr.%20Reddy's%20Laboratories%2C%20Ltd.), No. 3:11-cv-05579 (D.N.J.)

Parties and accused product. The plaintiffs are Helsinn Healthcare S.A., a privately held Swiss specialty pharmaceutical company based in Lugano, and Roche Palo Alto LLC, which appears as co-assignee on the patents (palonosetron originated as Syntex compound RS-25259; Roche acquired Syntex and later assigned its undivided interest to Helsinn — the PTO record in PGR2016-00007 notes Roche "previously a co-assignee" that "assigned to Helsinn all right, title, and interest"). Helsinn is a branded operating company, not an NPE — it markets Aloxi® (palonosetron hydrochloride injection, NDA 021372, approved July 25, 2003), a 5-HT₃ receptor antagonist for chemotherapy-induced and post-operative nausea and vomiting, with roughly $600 million in annual worldwide sales per Helsinn's own prosecution materials. The defendants are all generic ANDA filers: Dr. Reddy's Laboratories, Ltd. / Inc., Sandoz Inc., and Teva Pharmaceuticals USA, Inc. / Teva Pharmaceutical Industries, Ltd. The accused technology is each defendant's proposed generic palonosetron HCl intravenous solution at two strengths — 0.25 mg/5 mL (CINV indication) and 0.075 mg/1.5 mL (PONV indication) — filed with Paragraph IV certifications against the Orange Book–listed Aloxi patents, making this a straight 35 U.S.C. § 271(e)(2)(A) Hatch-Waxman case.

Patents and procedural posture. The '724 patent, "Liquid Pharmaceutical Formulations of Palonosetron" (Calderari et al., filed July 21, 2005 as a continuation of PCT/EP2004/000888, claiming priority to a Jan. 30, 2003 provisional; issued May 24, 2011), claims a shelf-stable aqueous palonosetron solution defined by a low concentration (0.05 mg/mL), an acidic buffer (pH ~4–6), a tonicifying agent (mannitol), and a stabilizing agent (EDTA); Helsinn asserted claims 2 and 9. One correction to the case metadata: this docket (11-5579, filed September 23, 2011) was the complaint directed principally at the '424 patent, which had issued June 14, 2011; the '724 and '725 patents were pleaded in the earlier-filed companion case, No. 11-3962 (D.N.J., 2011). That distinction became academic because the court consolidated the actions — 11-5579 and 13-5815 (the '219 patent case) were consolidated into lead case No. 11-3962 by stipulation and order entered May 29, 2014 (Dkt. 174), after which the four patents ('724, '725, '424, '219) were tried together and the '724 patent was unquestionably at issue against all three defendant groups. The case sat before Judge Mary L. Cooper, with Magistrate Judge Douglas E. Arpert, in the Trenton vicinage of the District of New Jersey, a venue that mattered both because Helsinn's U.S. commercial operations are New Jersey-centered and because the district had developed a deep Aloxi docket — a point Judge Cooper expressly relied on in Helsinn v. Hospira (Apr. 5, 2016) in finding specific jurisdiction over out-of-state ANDA filers, noting the state's interest given the many related palonosetron cases. Sandoz exited by consent judgment and dismissal on December 31, 2014 (Dkt. 247); Dr. Reddy's settled and stipulated to dismissal on October 16, 2015, mid-trial-to-judgment (Dkt. 355); after an 11-day bench trial in June 2015 and closing arguments on August 12, 2015, the court entered final judgment for Helsinn on November 16, 2015 (Dkts. 360, 361), holding the '724, '725, and '424 patents valid and infringed by both of Teva's proposed strengths and the '219 patent valid and infringed as to the 0.25 mg product only.

Why it is notable. The case became the most consequential U.S. on-sale-bar decision in a generation. On appeal (Fed. Cir. No. 16-1284), the Federal Circuit reversed, holding all asserted claims — including the '724 claims — invalid under § 102 because Helsinn's April 2001 supply-and-purchase agreement with MGI Pharma/Eisai, publicly filed as an SEC exhibit, was an invalidating commercial offer for sale before the January 30, 2002 critical date, and that the AIA did not change the meaning of "on sale" (Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., 855 F.3d 1356 (Fed. Cir. 2017); rehearing en banc denied Jan. 16, 2018). The Supreme Court affirmed on January 22, 2019 (Helsinn v. Teva, 586 U.S. ___, 139 S. Ct. 628), holding that a sale need not publicly disclose the invention to trigger the bar — a ruling now cited in virtually every commercial-transaction invalidity dispute. The PTAB linkage is equally instructive: Helsinn's patents largely survived the Board (Dr. Reddy's filed IPR2015-01551 against the '724 patent on July 3, 2015, per the Patexia docket, and parallel DRL petitions against the '094 and '942 patents were denied institution on October 14, 2015 and August 17, 2016 respectively; Accord's IPR on the '219 patent was denied institution on November 24, 2014), yet fell in district court on a § 102 ground that is unavailable in IPR under § 311(b) — a textbook illustration of the PTAB/litigation asymmetry. Commercially, the family was the last line of Orange Book defense for a drug whose listed patents ran to January 30, 2024 (July 30, 2024 with pediatric exclusivity), and

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

I'll research this case across the docket, court opinions, PTAB, and trade press.

Litigation Timeline — Helsinn Healthcare S.A. v. Dr. Reddy's Laboratories, Ltd., No. 3:11-cv-05579 (D.N.J.)

Critical framing note on the case number. No. 11-5579 is not a standalone case. It is the second-filed Helsinn/Aloxi® Hatch‑Waxman action in D.N.J., which was consolidated on 2011‑10‑27 into the lead case, No. 11‑3962 (MLC)(DEA), before Judge Mary L. Cooper. The consolidated lead case (11‑3962 + 11‑5579 + later 13‑5815) is the case that went to an 11‑day bench trial, was appealed, and reached the Supreme Court. Everything below treats 11‑5579 as a member of that consolidated proceeding, and notes where a development belongs to the lead case rather than to 11‑5579 itself. The '724 patent was asserted in the lead case (11‑3962), not in the 11‑5579 complaint; 11‑5579's own contribution was the '424 patent.

1. Filing and initial pleadings

2011‑07‑15 (approx.) — No. 11‑3962 filed (lead). Helsinn Healthcare S.A. and Roche Palo Alto LLC sued Dr. Reddy's Laboratories, Ltd./Inc. and Sandoz Inc. under 35 U.S.C. § 271(e)(2)(A), asserting the '724 and '725 patents against the first ANDA filers (DRL ANDA No. 201533; Sandoz ANDA No. 202521).

2011‑08‑31 — DRL answer and counterclaims in 11‑3962 (ECF No. 33). DRL pleaded invalidity counterclaims against the '724 patent, among others. This is the counterclaim that later drove the separate '724 action, No. 12‑2867. (Cited at Helsinn v. Dr. Reddy's, No. 12‑2867, slip op. at 2.)

2011‑09‑23 — No. 11‑5579 filed (the instant case number). Helsinn and Roche filed a second complaint against all five defendants — Dr. Reddy's Ltd., Dr. Reddy's Inc., Sandoz Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries, Ltd. — captioned in the complaint as Civil Action No. 3:11‑cv‑05579‑MLC‑DEA. The new matter was the '424 patent, triggered by Teva's Paragraph IV notice directed to that patent; the complaint also sought § 271(e)(2) declarations as to Teva's ANDA No. 090713 covering both the 0.25 mg/5 mL and 0.075 mg/1.5 mL palonosetron IV products. Source: complaint text at https://www.scribd.com/document/66585740/Helsinn-Healthcare-et-al-v-Dr-Reddy-s-Laboratories-et-al.

2011‑10‑24 — DRL's answer and counterclaim, and Sandoz's answer and counterclaims, in 11‑5579. Both challenged validity.

2011‑11‑03 — Teva's extension. Letter order (Magistrate Judge Douglas E. Arpert) extending Teva's response deadline from 2011‑11‑07 to 2011‑12‑05.

2011‑12‑05 — Teva's answer in 11‑5579 (Teva USA and Teva Ltd.), followed by Teva's Dec. 1, 2011 L. Pat. R. 3.6(c) invalidity contentions.

2011‑10‑27 — Consolidation order. 11‑5579 consolidated into 11‑3962 as the lead case. Subsequent filings were docketed on the 11‑3962 docket with the consolidated caption "Civil Action Nos. 11‑3962, 11‑5579, [13‑5815] (consolidated)." Docket: https://www.courtlistener.com/docket/[4310416](/patent/4310416)/helsinn-healthcare-sa-v-dr-reddys-laboratories-ltd/

2011‑11‑17 — Plaintiffs' replies to the DRL and Sandoz counterclaims.

Practical significance: the '724 patent entered this litigation through the DRL ANDA track (11‑3962), which is why 11‑5579 — the numerically-prompted case in your metadata — is not itself the '724 vehicle.

2. Pre-trial motions of substance

2012‑06‑26 → early 2013 — DRL's non-infringement motion in No. 12‑2867 (the '724-only case). In the parallel action No. 12‑2867, DRL moved to dismiss or for summary judgment of non-infringement of the '724 patent (Dkt. 13), and Helsinn cross-moved for partial summary judgment of infringement (Dkt. 26). Judge Cooper denied both without prejudice by an order to show cause dated 2012‑12‑17, then declined to reach infringement first, holding that "validity has the greater public importance" (Cardinal Chem. Co. v. Morton Int'l), and stayed and administratively terminated 12‑2867 pending the validity determination in 11‑3962. Opinion: https://cases.justia.com/federal/district-courts/new-jersey/njdce/3:2012cv02867/[274275](/patent/274275)/37/0.pdf. (Exact opinion date not confirmed from the face of the PDF; it followed the 12‑17‑12 OTSC.)

2013‑02‑15 / 2013‑03‑15 — Teva's motion to amend its invalidity contentions. Teva sought leave to amend/supplement its § 103 and § 112 theories; briefing is in the Supreme Court joint appendix (Nos. 17‑1229). The motion is strategically notable because the on‑sale‑bar theory that ultimately decided the case depended on the 2001 Helsinn–MGI License and Supply Agreements, which Teva had to get into the case. **I

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

I'll research this docket and the counsel involved.

Bottom line

This is Helsinn Healthcare S.A. et al. v. Dr. Reddy's Laboratories, Ltd. et al., No. 3:11-cv-05579-MLC-DEA (D.N.J., filed Sept. 23, 2011, Judge Mary L. Cooper, Mag. J. Douglas E. Arpert). Plaintiffs are Helsinn Healthcare S.A. and Roche Palo Alto LLC.

The plaintiff-side team was a two-tier structure: Paul Hastings LLP (New York) as outside/lead patent counsel for both plaintiffs, Loeb & Loeb LLP (New York) for Roche Palo Alto, and Saul Ewing LLP (Newark) as New Jersey local counsel of record. Note the drafting quirk: the Paul Hastings and Loeb & Loeb lawyers are printed under an "Of Counsel" heading in the complaint's signature block, but that label reflects their pro hac vice outside-counsel status, not a subordinate role — Saul Ewing was the firm formally appearing as counsel of record.

Plaintiff-side counsel of record

Attorney Role Firm / office Note
Joseph M. O'Malley, Jr. Lead outside counsel (Paul Hastings); listed under "Of Counsel" in D.I. 1 Paul Hastings LLP, 75 E. 55th St., New York, NY Paul Hastings life-sciences patent litigation partner; the senior name on the Helsinn/Roche pleading block and the firm's principal Helsinn-side lawyer through the Aloxi ANDA program.
Bruce M. Wexler Outside counsel, Paul Hastings Paul Hastings LLP, New York Registered on the complaint signature block for both plaintiffs; longtime Paul Hastings Hatch-Waxman/§ 271(e)(2) litigator.
Eric W. Dittmann Outside counsel, Paul Hastings Paul Hastings LLP, New York On the D.I. 1 signature block; later docketed a formal Notice of Appearance for Helsinn in the related Aloxi case, Helsinn v. Sagent, No. 2:16-cv-00173 (D.N.J.).
David M. Conca Outside counsel, Paul Hastings Paul Hastings LLP, New York On the D.I. 1 signature block for both plaintiffs.
Gary Ji Outside counsel, Paul Hastings Paul Hastings LLP, New York On the D.I. 1 signature block for both plaintiffs.
Angela C. Ni Outside counsel, Paul Hastings Paul Hastings LLP, New York On the D.I. 1 signature block; also docketed a Notice of Appearance for Helsinn in the related Sagent case.
Mark E. Waddell Outside counsel for Roche Palo Alto LLC only Loeb & Loeb LLP, 345 Park Ave., New York, NY Separate signature block in D.I. 1 for the Roche entity; Roche was a co-assignee of the palonosetron formulation patents.
Charles M. Lizza Local counsel of record (New Jersey) Saul Ewing LLP, One Riverfront Plaza, Suite 1520, Newark, NJ Dean of Saul Ewing's New Jersey patent litigation group; the firm's Hatch-Waxman practice handles a large share of the D.N.J. ANDA docket. Listed on D.I. 1 and on the docket as a plaintiff-side attorney.
William C. Baton Local counsel of record (New Jersey) Saul Ewing LLP, Newark, NJ Same role as Lizza; appears on the D.I. 1 signature block and in the docket's "represented by" field for plaintiffs across the Helsinn Aloxi cases.

Related team members seen in the consolidated/companion Aloxi cases (not verified as appearing in 05579 itself): Isaac S. Ashkenazi (Paul Hastings) and Sarah Ann Sullivan (Saul Ewing) entered appearances for Helsinn/Roche in Helsinn v. Sagent, No. 2:16-cv-00173 — treat those as related-case appearances only.

Sourcing and caveats

  • The counsel list above is drawn from the signature blocks of the complaint (D.I. 1) in No. 3:11-cv-05579, as reproduced in the publicly posted complaint (Scribd copy) and corroborated by the parallel complaint text made public in an IPR exhibit (USPTO PTAB document).
  • No formal "lead counsel" designation appears on the docket. The lead/of-counsel/local-counsel characterizations above are inferred from the pleading block (Paul Hastings first, Saul Ewing as the New Jersey firm), which is the standard D.N.J. structure.
  • I did not individually pull each pro hac vice admission order for the Paul Hastings lawyers in 05579; those admissions are standard in this District but the specific order numbers were not verified. If you need the pro hac vice orders, they would be docketed in the consolidated lead case, No. 3:11-cv-03962-MLC-DEA.
  • No sealed filings affecting counsel were identified; nothing suggests counsel identity is under seal. (The confidentiality orders in this litigation covered discovery/expert material, not appearances.)
  • Patent caveat: the 05579 complaint as reported asserted U.S. Patent No. 7,960,424 (issued June 14, 2011), not the '724 patent; the '724 and '725 patents were asserted in the earlier-filed companion case, No. 3:11-cv-03962. The two cases were consolidated on October 27, 2011 under No. 11-3962, which is why '724 appears in litigation databases tied to 05579. The same Paul Hastings/Saul Ewing team represented plaintiffs in the consolidated action.
  • Post-2011 posture (background, not counsel-related): consolidated action tried to a bench verdict for Helsinn in Nov. 2015; appealed (Fed. Cir. No. 16-1284, 855 F.3d 1356 (2017)); rehearing denied en banc Jan. 16, 2018; Supreme Court granted cert (No. 17-1229) and affirmed on the on-sale bar in Jan. 2019. I have not verified here which individual attorney argued at the Federal Circuit or Supreme Court, so I am not attributing appellate argument roles.

If you want, I can next pull the pro hac vice orders and any substitution/withdrawal entries from the consolidated 11-3962 docket to give you a dated appearance chronology per attorney.

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

I'll research this docket and the counsel of record.

Bottom line first: the docket posture matters here

Case No. 3:11-cv-05579 (MLC)(DEA) is Helsinn Healthcare S.A. et al. v. Dr. Reddy's Laboratories, Ltd.; Dr. Reddy's Laboratories, Inc.; Sandoz Inc.; Teva Pharmaceuticals USA, Inc.; and Teva Pharmaceutical Industries, Ltd., filed 9/23/2011 in the Trenton vicinage before Judge Mary L. Cooper and Magistrate Judge Douglas E. Arpert. (Justia docket)

Two corrections to the existing summary that affect any counsel list:

  • The 11-5579 complaint itself asserted only the '424 patent. U.S. Pat. No. 7,947,724 was asserted in the companion case, No. 11-3962 (claims 2 and 9). 11-5579 was then consolidated into 11-3962 by order of Mag. J. Arpert dated 10/27/2011, with all papers thereafter maintained in 11-3962. (Consolidation order, Dkt. 68 in 11-3962, CourtListener)
  • Practically, therefore, the "'724 case" defense team is the consolidated defense team in 11-3962, where the '724 was tried (Dkt. 361, Final Judgment, 11/16/2015, holding '724 claims 2 and 9 valid and infringed by Teva).

This matters because counsel appearances are recorded in both dockets, and the 11-5579 docket is thin post-consolidation. My sourcing below is strongest for Teva and weaker for Dr. Reddy's and Sandoz — I flag that expressly rather than filling gaps.

Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd.

Lead trial and appellate counsel — Winston & Strawn LLP

Attorney Role Firm / Office Note
George C. Lombardi Lead counsel (trial + appeal) Winston & Strawn LLP, 35 W. Wacker Dr., Chicago Longtime leader of Teva's ANDA defense; listed first on the corrected Federal Circuit brief in Helsinn v. Teva, No. 2016-1284.
Steffen N. Johnson Lead appellate counsel; argued for Teva at the Supreme Court in Helsinn v. Teva, 586 U.S. 731 (2019) (on-sale bar under AIA § 102) Winston & Strawn LLP, 1700 K St. N.W., Washington, D.C. The 2019 SCOTUS win (secret sales can be invalidating prior art) is the headline result.
Jovial Wong Core case team; de facto docket lead in D.N.J. Winston & Strawn LLP, Washington, D.C. Filed the May 21, 2012 claim-construction declaration as "an associate with Winston & Strawn LLP, attorneys for Defendants Teva" (Dkt. 89 in 11-3962). Now a partner; frequent ACI Paragraph IV panelist on Helsinn v. Teva.
Julia M. Johnson Case team (trial) Winston & Strawn LLP, Chicago Appeared at the Sept. 7, 2012 status conference in 11-3962.
Andrew C. Nichols Case team (appellate) Winston & Strawn LLP, Washington, D.C. Named on the Federal Circuit brief.
Karl A. Leonard; Tyler G. Johannes; Lynn MacDonald Ulrich; Lindsay Beyer; Brandon Barker; David Luger Case team (associates/counsel of record on briefs) Winston & Strawn LLP (Chicago / D.C.) Named in the Fed. Cir. Rule 47.5 disclosure statement of trial and appellate counsel.

Local counsel — Lite DePalma Greenberg LLC, Newark, NJ

Attorney Role Note
Michael A. Patunas Local counsel of record (D.N.J. filer) ECF filer on Teva's D.N.J. submissions (e.g., Dkt. 89 in 11-3962).
Mayra Velez Tarantino Local counsel (appearances) Listed among counsel appearing for Teva at the Sept. 7, 2012 proceeding (Minutes of Proceedings, Dkt. 101 in 11-3962).

Source for the Winston team: Corrected Brief for Defendants-Appellants, Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., No. 2016-1284 (Fed. Cir. filed Mar. 7, 2016) (PDF); Dkt. 89 and Dkt. 101 in 11-3962 (archive.org minutes).

Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc.

Appearances recorded at the Sept. 7, 2012 status conference (Minutes, Dkt. 101 in 11-3962) list six attorneys "for defendant DR. REDDY'S": Stuart Sender, Michael Imbacuan, Howard Wang, Kerry McTigue, Aaron Lukas, and Andrew Niemeroff.

I was not able to verify the firm affiliations of this group from a reliable source in this pass, and I will not guess at them. What I can say with confidence:

  • They appeared of record for DRL in the consolidated action in which the '724 was asserted, so they are the correct counsel-of-record group to pull from the docket.
  • The natural next step is the 11-5579 and 11-3962 docket sheets' "ATTORNEY TO BE NOTICED" blocks (ECF Nos. 1–30 in 11-5579, filed Sept.–Oct. 2011), which will give firm, address and bar number for each. I'd rather hand you that as a verification task than assert a firm name I could not confirm.
  • DRL's defense succeeded in narrowing the case: DRL was dismissed by stipulation on October 16, 2015 (Dkt. 355 in 11-3962), after a settlement reflected in the Oct. 6, 2015 agreement discussed in later D.N.J. litigation. (Dkt. 53 discussion in D.N.J. 15-cv-…, CourtListener)

Sandoz Inc.

Sandoz's counsel are not identified in the sources I could access, and I am not going to name anyone speculatively. Sandoz appeared and litigated actively — it was Sandoz that first obtained leave in September 2012 to amend its invalidity contentions to add the § 102 on-sale bar defense that ultimately carried the day at the Supreme Court (see Teva's motion to amend, Dkt. 124.1 in 11-3962, archive.org) — so its counsel team is substantively important even though Sandoz exited early. Sandoz was dismissed by consent on December 31, 2014 (Dkt. 247 in 11-3962), with a consent judgment and injunction tied to ANDA No. 202521.

Note also that in the parallel Hospira branch of the Helsinn litigation, the counsel lineups were different (Saiber LLC for Hospira; Saul Ewing's Charles M. Lizza and William C. Baton, with Paul Hastings and Loeb & Loeb, for Helsinn). Do not carry those names over to Sandoz here.

Caveats and verification notes

  1. Not sealed, but incomplete from free sources. The appearances are public; the content of much of the record is sealed (confidentiality designations appear throughout, e.g., Dkts. 174, 124.1 in 11-3962). Counsel identity is not the sealed part — my gaps are search-coverage gaps, not sealing.
  2. Consolidation means the operative docket is 11-3962. A PACER pull of the full docket report for 11-5579 will show the initial appearances (Sept.–Oct. 2011) for all five defendants before consolidation; the 11-3962 docket carries everything after 10/27/2011.
  3. Case terminated. Final judgment entered 11/16/2015 (Dkt. 361 in 11-3962) against Teva; Fed. Cir. 855 F.3d 1356 (2017); SCOTUS 586 U.S.